Management and grading of EGFR inhibitor-induced cutaneous toxicity.
Name:
fon-2018-0187.pdf
Size:
2.943Mb
Format:
PDF
Description:
Open access full text article
Authors
Beech, JanetteGermetaki, Theodora
Judge, M
Paton, Nina
Collins, Joanne
Garbutt, Abigail
Braun, Michael S
Fenwick, J
Saunders, Mark P
Affiliation
Department of Medical/Clinical Oncology, Christie Hospital, 550 Wilmslow Road, Manchester, UKIssue Date
2018-05-04
Metadata
Show full item recordAbstract
Cutaneous toxicities associated with EGFR inhibitors (EGFRIs) have a significant impact on patient treatment continuation, quality of life and healthcare resource utilization. This paper reviews the current prophylaxis and management of EGFRI-induced cutaneous toxicities in patients with colorectal cancer, and combines these findings with the authors' clinical expertise to define a novel algorithm for healthcare professionals managing patients receiving EGFRIs. This tool includes a grading system based on the location, severity and psychological impact, and provides a standard prescription pack, advice on prophylaxis/self-management of cutaneous symptoms for patients initiating EGFRIs, and essential guidance on subsequent review and treatment escalation. It aims to optimize treatment of metastatic colorectal cancer by minimizing cutaneous toxicities to maintain dose intensity and efficacy of EGFRI-based chemotherapy.Citation
Management and grading of EGFR inhibitor-induced cutaneous toxicity. 2018 Future OncolJournal
Future OncologyDOI
10.2217/fon-2018-0187PubMed ID
29727211Type
ArticleLanguage
enISSN
1744-8301ae974a485f413a2113503eed53cd6c53
10.2217/fon-2018-0187
Scopus Count
Collections
Related articles
- Reducing Skin Toxicities from EGFR Inhibitors with Topical BRAF Inhibitor Therapy.
- Authors: Lacouture ME, Wainberg ZA, Patel AB, Anadkat MJ, Stemmer SM, Shacham-Shmueli E, Medina E, Zelinger G, Shelach N, Ribas A
- Issue date: 2021 Sep
- Quantitative assessment of skin disorders induced by panitumumab: a prospective observational study.
- Authors: Takahashi H, Saito Y, Sugawara K, Sato M, Tairabune T, Ujiie H, Asaka J, Kudo K
- Issue date: 2024 Apr
- HLA-C*15:02 and epidermal growth factor receptor inhibitor-induced erosive pustular dermatosis of the scalp.
- Authors: Zhang Y, Grice S, Wang N, Liu Y, Zhao Q, Liu T, Sun L, Mi Z, Wang J, Yu G, Zhang F, Meng X, Liu H, Naisbitt DJ, Sun Y, Zhang F
- Issue date: 2023 Oct 25
- A review of cutaneous toxicities from targeted therapies in the treatment of colorectal cancers.
- Authors: Urban C, Anadkat MJ
- Issue date: 2013 Sep
- "It's Like You Stuck a Pin in It:" African American/Black Patients Describe Cutaneous Toxicity From Epidermal Growth Factor Receptor Inhibitors.
- Authors: Tran NH, Nguyen PL, Martin NA, Asiedu G, Le-Rademacher JG, Jatoi A
- Issue date: 2023 Mar